Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tamsulosin Hydrochloride

FDA-approved product (capsule, oral), marketed as Flomax, Tamsulosin Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Tamsulosin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis73.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tamsulosin Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tamsulosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia

    NCT02245529 · start 2005-03

    Registered record
    Registry ID
    NCT02245529
    Conditions
    Prostatic Hyperplasia
    Interventions
    Tamsulosin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-03
    Completion
    Not recorded
    Enrolment
    982

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionTamsulosin
    PhaseNot recorded
    Registry statusCompleted

  • Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms

    NCT02245490 · start 2003-01

    Registered record
    Registry ID
    NCT02245490
    Conditions
    Prostatic Hyperplasia
    Interventions
    Tamsulosin HCl controlled release capsules; Matching placebo capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-01
    Completion
    Not recorded
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionTamsulosin HCl controlled release capsules; Matching placebo capsule
    PhasePhase 4
    Registry statusCompleted

  • Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)

    NCT02244320 · start 2002-09

    Registered record
    Registry ID
    NCT02244320
    Conditions
    Prostatic Hyperplasia
    Interventions
    Tamsulosin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2002-09
    Completion
    Not recorded
    Enrolment
    4,150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionTamsulosin
    PhaseNot recorded
    Registry statusCompleted

  • Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome

    NCT00239265

    Registered record
    Registry ID
    NCT00239265
    Conditions
    Urinary Tract Diseases
    Interventions
    Tamuslosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Diseases
    InterventionTamuslosin
    PhasePhase 3
    Registry statusCompleted

  • Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome

    NCT00239317

    Registered record
    Registry ID
    NCT00239317
    Conditions
    Urinary Tract Diseases
    Interventions
    Tamusulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Diseases
    InterventionTamusulosin
    PhasePhase 3
    Registry statusCompleted